Short Interest in Nykode Therapeutics AS (OTCMKTS:VACBF) Declines By 29.8%

Nykode Therapeutics AS (OTCMKTS:VACBF) was the target of a large decline in short interest during the month of March. As of March 13th, there was short interest totaling 743,685 shares, a decline of 29.8% from the February 26th total of 1,059,580 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days.

Nykode Therapeutics AS Stock Performance

VACBF opened at $0.38 on Friday. The company’s 50-day simple moving average is $0.34 and its two-hundred day simple moving average is $0.25. Nykode Therapeutics AS has a 52-week low of $0.16 and a 52-week high of $0.38.

About Nykode Therapeutics AS

Nykode Therapeutics AS (OTCMKTS:VACBF) is a clinical-stage biotechnology company based in Oslo, Norway, focused on the development of precisely targeted immunotherapies. The company’s proprietary platform is designed to deliver antigenic payloads directly to antigen-presenting cells, with the goal of eliciting potent and durable immune responses against both cancerous and infectious disease targets. By combining modular antigen design with novel delivery modalities, Nykode aims to drive next-generation vaccine and immunotherapy solutions.

The company’s clinical pipeline includes several lead candidates in oncology and infectious diseases.